selegiline has been researched along with Depression, Involutional in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 18 (58.06) | 29.6817 |
| 2010's | 11 (35.48) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Birkenhager, TK; Caiazza, C; Cattaneo, CI; de Bartolomeis, A; Fornaro, M; Gillman, K; Iasevoli, F; Rossano, F; Ruhé, HG; Sobrino, A; Solini, N; Stahl, S; Van den Eynde, V; Vellucci, A; Zotti, N | 1 |
| Citrome, L; Goldberg, JF; Portland, KB | 1 |
| Craig Nelson, J; Jang, S; Jung, S; Kimberly, BP; Pae, C; Patkar, AA | 1 |
| Jang, S; Jung, S; Nelson, JC; Pae, CU; Patkar, AA; Portland, KB | 1 |
| Azzaro, AJ; DelBello, MP; Emslie, G; Hochadel, TJ; Katic, A; Khan, A; Portland, KB | 1 |
| Byerly, MJ; Emslie, GJ; Mayes, TL; Nakonezny, PA | 1 |
| Bied, AM; Kim, J; Schwartz, TL | 1 |
| Cristancho, MA; Thase, ME | 1 |
| Miklya, I | 1 |
| DelBello, MP; Nandagopal, JJ | 1 |
| Kostenko, O; Malone, D; Wimbiscus, M | 1 |
| George, TP; McKee, SA; Weinberger, AH | 1 |
| Alexopoulos, GS | 1 |
| Amsterdam, JD; Bodkin, JA | 2 |
| Robinson, DS | 1 |
| Gaszner, P; Miklya, I | 2 |
| Gorman, JM | 1 |
| Masand, PS; Pae, CU; Patkar, AA | 1 |
| Feiger, AD; Rickels, K; Robinson, DS; Rynn, MA; Zimbroff, DL | 1 |
| Frampton, JE; Plosker, GL | 2 |
| Tobin, M | 1 |
| Amsterdam, JD; Robinson, DS | 1 |
| Azzaro, AJ; Campbell, BJ; Gilmor, ML; Moonsammy, G; Oren, DA; Robinson, DS; Yang, Y | 1 |
| Carlat, DJ | 1 |
| Amsterdam, JD; Campbell, BJ; Clayton, AH; Favit, A; Moonsammy, G; Piontek, CM; Yang, Y | 1 |
| Chari, G; Gold, M; Hauser, RA; Zesiewicz, TA | 1 |
| Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N | 1 |
16 review(s) available for selegiline and Depression, Involutional
| Article | Year |
|---|---|
Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations.
Topics: Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Major; Humans; Methylphenidate; Monoamine Oxidase Inhibitors; Selegiline | 2023 |
Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Administration, Cutaneous; Antidepressive Agents; Biomedical Research; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Research Design; Selegiline | 2013 |
Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials.
Topics: Administration, Cutaneous; Adult; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Psychophysiologic Disorders; Randomized Controlled Trials as Topic; Selegiline; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Weight Loss | 2014 |
A critical appraisal of the selegiline transdermal system for major depressive disorder.
Topics: Administration, Cutaneous; Antidepressive Agents; Depressive Disorder, Major; Drug Liberation; Humans; Hypertension; Medication Adherence; Selegiline; Transdermal Patch | 2015 |
Critical appraisal of selegiline transdermal system for major depressive disorder.
Topics: Administration, Cutaneous; Depressive Disorder, Major; Humans; Monoamine Oxidase Inhibitors; Selegiline; Skin Absorption; Transdermal Patch | 2016 |
The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Topics: Aging; Alzheimer Disease; Animals; Brain; Catecholamines; Depressive Disorder, Major; Dopamine; History, 20th Century; Humans; Monoamine Oxidase; Parkinson Disease; Phenethylamines; Rats; Selegiline | 2016 |
Selegiline transdermal system: a novel treatment option for major depressive disorder.
Topics: Administration, Cutaneous; Amyloid beta-Peptides; Animals; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome | 2009 |
MAO inhibitors: risks, benefits, and lore.
Topics: Administration, Cutaneous; Antidepressive Agents; Blood Pressure; Cheese; Depressive Disorder, Major; Feeding Behavior; Food-Drug Interactions; Humans; Hypertension; Monoamine Oxidase Inhibitors; Myocardium; Risk Factors; Selegiline; Tyramine | 2010 |
The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
Topics: Benzofurans; Catecholamines; Depressive Disorder, Major; Humans; Mesencephalon; Neuroprotective Agents; Selegiline; Serotonin Agents; Tryptamines | 2004 |
Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane.
Topics: Animals; Benzofurans; Depressive Disorder, Major; Humans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Selegiline; Tryptamines | 2006 |
Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
Topics: Administration, Cutaneous; Depressive Disorder, Major; Drug Interactions; Humans; Monoamine Oxidase Inhibitors; Phenelzine; Selegiline; Tranylcypromine | 2006 |
The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Humans; Hypertension; Hypotension, Orthostatic; Male; Middle Aged; Monoamine Oxidase Inhibitors; Selegiline; Serotonin Syndrome; Sexual Dysfunction, Physiological; Sleep Initiation and Maintenance Disorders | 2008 |
Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Placebos; Randomized Controlled Trials as Topic; Selegiline | 2007 |
Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Placebos; Randomized Controlled Trials as Topic; Selegiline; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological | 2007 |
Current issues in depression in Parkinson's disease.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Parkinson Disease; Psychomotor Performance; Selective Serotonin Reuptake Inhibitors; Selegiline | 1999 |
[Serotonin syndrome: report of a fatal case and review of the literature].
Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism; Fatal Outcome; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome | 2002 |
6 trial(s) available for selegiline and Depression, Involutional
| Article | Year |
|---|---|
Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
Topics: Administration, Cutaneous; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Monoamine Oxidase Inhibitors; Proportional Hazards Models; Recurrence; Risk Factors; Selegiline | 2013 |
A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.
Topics: Administration, Cutaneous; Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Selegiline; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2014 |
Differences in smoking expectancies in smokers with and without a history of major depression.
Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Psychiatric Status Rating Scales; Selegiline; Sex Factors; Smoking; Smoking Cessation; Surveys and Questionnaires; Young Adult | 2011 |
Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Personality Inventory; Selegiline; Treatment Outcome | 2002 |
Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
Topics: Administration, Cutaneous; Adult; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Monoamine Oxidase Inhibitors; Personality Inventory; Placebos; Psychiatric Status Rating Scales; Selegiline; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2006 |
Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Delivery Systems; Female; Humans; Kaplan-Meier Estimate; Male; Monoamine Oxidase Inhibitors; Patient Compliance; Patient Dropouts; Psychiatric Status Rating Scales; Secondary Prevention; Selegiline; Time Factors; Treatment Outcome | 2006 |
9 other study(ies) available for selegiline and Depression, Involutional
| Article | Year |
|---|---|
Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS).
Topics: Adolescent; Child; Depressive Disorder, Major; Female; Humans; Male; Models, Statistical; Neuroprotective Agents; Outcome Assessment, Health Care; Placebo Effect; Probability; Randomized Controlled Trials as Topic; Selegiline; Sensitivity and Specificity; Transdermal Patch | 2015 |
Pharmacotherapy for late-life depression.
Topics: Administration, Cutaneous; Adult; Age Factors; Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Humans; Monoamine Oxidase Inhibitors; Placebo Effect; Practice Guidelines as Topic; Psychotherapy; Selegiline; Treatment Outcome | 2011 |
Monoamine oxidase inhibitors: a new generation.
Topics: Administration, Cutaneous; Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Monoamine Oxidase Inhibitors; Selegiline | 2002 |
Leading the way: advances in the diagnosis, treatment, and management of neuropsychiatric illnesses.
Topics: Administration, Cutaneous; Administration, Topical; Brain; Depressive Disorder, Major; Humans; Mental Disorders; Monoamine Oxidase Inhibitors; Phenelzine; Psychiatry; Selegiline; Somatoform Disorders; Tranylcypromine | 2006 |
Transdermal selegiline (Emsam).
Topics: Administration, Cutaneous; Antiparkinson Agents; Clinical Trials as Topic; Depressive Disorder, Major; Double-Blind Method; Drug Interactions; Humans; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline | 2006 |
Selegiline transdermal system: in the treatment of major depressive disorder.
Topics: Administration, Cutaneous; Adult; Depressive Disorder, Major; Drug Interactions; Female; Humans; Male; Monoamine Oxidase Inhibitors; Selegiline | 2007 |
Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
Topics: Administration, Cutaneous; Antidepressive Agents; Depressive Disorder, Major; Drug Interactions; Humans; Monoamine Oxidase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Selegiline; Treatment Outcome; Tyramine | 2007 |
Selegiline transdermal system in major depressive disorder: profile report.
Topics: Administration, Cutaneous; Area Under Curve; Depressive Disorder, Major; Diarrhea; Drug Administration Schedule; Half-Life; Headache; Humans; Monoamine Oxidase Inhibitors; Selegiline; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Xerostomia | 2007 |
Commentary on the treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Monoamine Oxidase Inhibitors; Selegiline | 2007 |